Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
CA 2118119 C · Owner: Amgen Boulder Inc. · Inventors: Russell, Deborah A.; Thompson, Robert C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to methods for treating or preventing diseases that are IL-1 mediated diseases or TNF mediated diseases, including arthritis, septic shock inflammatory bowel disease, ischemia , injury reperfusion injury, pulmonary fibrosis and adult respiratory distress syndrome. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and a TNF inhibitor. In a preferred embodiment the IL-1 inhibitor is human recombinant IL-1ra and the TNF inhibitor is human recombinant 30kDa TNF inhibitor. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and a TNF inhibitor useful in such methods.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 28, 1993 and granted July 31, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 28, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 28, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.